mmaf-monomethyl-auristatin-f

Description: Monomethyl auristatin F (also known as MMAF) is a highly potent tubulin/antimitotic inhibitor and an antineoplastic agent used as a warhead in ADCs (antibody-drug conjugates) such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. MMAF is actually desmethyl-auristatin F; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin F itself.

References:

1. LeeJW, et al. EphA2 targeted chemotherapy using an antibody drug conjugatein endometrial carcinoma. Clin Cancer Res. 2010 May 1; 16(9):2562-70.

2. LeeJJ, et al. Enzymatic prenylation and oxime ligation for the synthesisof stable and homogeneous protein-drug conjugates for targeted therapy.Angew Chem Int Ed Engl. 2015 Oct 5; 54(41):12020-4.

3. Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry. Bioorg Med Chem. 2015 Nov 15; 23(22):7150-7.

Related CAS: 1799706-65-2 (sodium); 1415246-68-2 (HCl)